Cooley LLP advised Molecular Templates on the deal.
Clinical-stage biopharmaceutical company Molecular Templates (MTEM) announced its strategic research collaboration with Bristol Myers Squibb to discover and develop therapies designed for specific oncology targets. The collaboration will seek to discover new molecules utilizing MTEM’s next-generation engineered toxin body (ETB) platform.
Under the terms of the agreement, MTEM will receive an upfront payment of $70 million and will be eligible to receive up to approximately $1.3 billion in near-term and development, regulatory and sales milestone payments as well as tiered royalty payments on future sales.
MTEM will conduct research activities for the discovery of next generation ETBs – a new class of targeted therapeutics – for multiple targets. Bristol Myers Squibb will have the option to obtain an exclusive worldwide license to develop and commercialize ETBs directed to each selected target. Following the exercise of the option, Bristol Myers Squibb would be solely responsible for developing and commercializing the licensed ETBs.
Lawyers Alison Freeman-Gleason (Picture) and Kristy Brady led the Cooley team advising MTEM.
Law Firms: Cooley LLP;
Clients: Molecular Templates Inc.;